Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.16 | N/A | +0.48% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.16 | N/A | +0.48% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the challenges in the current market environment. They emphasized their commitment to long-term growth without providing detailed guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company expressed a focus on maintaining operational stability.
AbbVie's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by over 6% likely due to a lack of revenue details and future guidance, which may have raised concerns among investors about the company's outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SHERWIN-WILLIAMS CO
Apr 26, 2022